Axitinib is a targeted therapy drug used in the treatment of metastatic renal cell carcinoma (RCC). It works to block certain proteins, known as vascular endothelial growth factor receptors (VEGFRs), from growing and spreading. This allows for improved outcomes in patients with this form of cancer. However, like other treatments, there are risks and side effects associated with its use. In this article, we will discuss what you need to know about axitinib in order to make informed decisions about your treatment plan. We will explore how it works, the different types available, common side effects associated with use, and other important information that can help you feel confident in your choice of treatment.
Axitinib is a targeted cancer therapy that works by inhibiting the activity of tyrosine kinase enzymes. These enzymes are involved in the growth and spread of cancer cells. Axitinib is used to treat renal cell carcinoma (RCC), a type of kidney cancer. It is typically used after other treatments, such as surgery, have failed. Axitinib may also be used to treat other types of cancers, such as thyroid cancer or non-small cell lung cancer (NSCLC).
Axitinib belongs to a class of drugs known as kinase inhibitors. Kinase inhibitors work by blocking the activity of certain enzymes, which can help stop the growth and spread of cancer cells. Axitinib is a targeted therapy, which means it targets specific molecules that are involved in the growth and spread of cancer cells. Axitinib inhibits the activity of tyrosine kinase enzymes. These enzymes are found in healthy cells, but they are overactive in cancer cells. By inhibiting these enzymes, axitinib can help stop the growth and spread of cancer cells.
Axitinib works by inhibiting the vascular endothelial growth factor (VEGF) receptor. This protein is responsible for the growth and development of new blood vessels. When the VEGF receptor is inhibited, blood vessel growth is prevented, which in turn slows down the growth of cancerous tumors. Axitinib has been shown to be effective in treating several types of cancer, including renal cell carcinoma, gastrointestinal stromal tumor, and thyroid cancer.
The most common side effects of Axitinib are diarrhea, fatigue, high blood pressure, loss of appetite, and nausea. Less common side effects include bleeding, brain hemorrhage, heart attack, kidney failure, and liver damage. Some of the more rare side effects include hair loss, skin rash, and vision changes.
If you miss a dose of axitinib, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Axitinib is a powerful cancer-fighting drug that can be used to treat certain types of tumors. While the side effects and risks associated with its use must always be taken into account, it has been proven effective in many cases. With careful monitoring and guidance from your oncologist or hematologist, axitinib can be incorporated into an individualized treatment plan that helps you manage your disease while minimizing any potential adverse reactions.
1.
Adipocytes in the bone marrow offer early indicators of the development of multiple myeloma from MGUS.
2.
Treatment of Smoldering Myeloma Cuts Progression Rate in Half
3.
Chemotherapy combination boosts overall survival in patients with EGFR-mutant non-small cell lung cancer
4.
Study identifies new target for obesity-related breast cancer
5.
unhealthy sleeping habits and the risk of esophageal adenocarcinoma.
1.
Vaccines that can help prevent cancer
2.
Chondroma: What it is and How it Affects Your Health
3.
From Muscle Soreness to Improved Endurance: The Benefits of Monitoring Lactic Acid Levels
4.
Uncovering the Mystery of Burkitt's Lymphoma: A New Hope for Treatment
5.
Claudin-18.2 in Gastric Cancer: Tumor-Stroma Crosstalk and Disease Progression
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
2.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation